Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

Key facts

Sponsor

Queen Saovabha Memorial Institute

Principal Investigator

Suda Sibunruang, MD

Queen Saovabha Memorial Institute. Faculty of Medicine, Chulalongkorn university

Intervention

rabies vaccine(biological)

Enrollment

40 target

Eligibility

18-60 years · All sexes

Timeline

2016 – 2023

Study locations (1)

• Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand

Collaborators

Chulalongkorn University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rabies

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07500207
  A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
  Changchun BCHT Biotechnology Co.
• ACTIVE NOT RECRUITINGPHASE3NCT07275645
  A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
  Ab&B Bio-tech Co., Ltd.JS
• ENROLLING BY INVITATIONPHASE1NCT07338786
  A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)
  Changchun BCHT Biotechnology Co.
• RECRUITINGPHASE1NCT07021703
  A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
  Ningbo Rongan Biological Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT06998004
  A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
  AstriVax Therapeutics
• ENROLLING BY INVITATIONPHASE3NCT05545371
  Prevention of Rabies With Four Doses of Rabies Vaccine
  Changchun Zhuoyi Biological Co., Ltd
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04270838
  A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
  University of Oxford

See all trials for Rabies →